Free Newsletter
Success in traveler's diarrhea jab trial
A new study published in Infection and Immunity says that an experimental vaccine against C. jejune, a major cause of traveler's diarrhea, worked to protect mice and monkeys in a clinical study and may well prove effective in humans as well.
"We are very excited about these results," says Dr. Patricia Guerry, the senior investigator. C. jejune also plays a role in other ailments, such as inflammatory bowel disease. Guerry has been working with grant money from the National Institute of Allergy and Infectious Diseases.
In particular, Guerry noted that monkeys were completely protected from diarrhea caused by C. jejune. Traveler's diarrhea is a common ailment for Americans journeying abroad, and it has inspired several development programs by biotech companies.
- read the story from Reuters
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: